Exhaled nitric oxide in stable adult cystic fibrosis patients, during exacerbation and following CFTR-modifying treatment

Eur Respir J. 2019 May 30;53(5):1802259. doi: 10.1183/13993003.02259-2018. Print 2019 May.

Authors

Stefanie Vincken¹, Sylvia Verbanck¹, Elke De Wachter², Eef Vanderhelst¹

Affiliations

¹ Division of Respiratory Diseases, Dept of Medicine, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Brussels, Belgium.
² Dept of Paediatrics, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Brussels, Belgium.

PMID: 30819814
DOI: 10.1183/13993003.02259-2018

No abstract available

Publication types

Letter
Observational Study

MeSH terms

Adult
Aminophenols / therapeutic use
Aminopyridines / therapeutic use
Benzodioxoles / therapeutic use
Breath Tests
Cystic Fibrosis / drug therapy*
Cystic Fibrosis / metabolism
Cystic Fibrosis Transmembrane Conductance Regulator
Disease Progression
Drug Combinations
Exhalation
Female
Humans
Male
Nitric Oxide / analysis*
Prospective Studies
Quinolones / therapeutic use
Young Adult

Substances

Aminophenols
Aminopyridines
Benzodioxoles
Drug Combinations
Quinolones
lumacaftor, ivacaftor drug combination
Cystic Fibrosis Transmembrane Conductance Regulator
ivacaftor
Nitric Oxide